

# Navigating Treatment Options

For Patients With HR+/HER2- Advanced Breast Cancer



**Friday, 2 December 2022 | 12:45–14:15 SGT**

**Summit 2, Level 3, Suntec Singapore Convention & Exhibition Centre, Singapore**



**Richard Hendry de Boer, MBBS, FRACP**

Consultant Medical Oncologist  
Peter MacCallum Cancer Centre and  
the Epworth-Freemasons Hospital  
Melbourne, Australia



**Yen-Shen Lu, MD, PhD**

Division Chief and Professor of Medical Oncology  
Department of Oncology  
National Taiwan University Hospital  
Taipei, Taiwan



**Soo Chin Lee, MBBS, FRCP**

Medical Oncologist and Professor  
National University Cancer Institute  
Singapore

## Meeting objectives:

- Review recent evidence from CDK4/6 inhibitor trials that may impact treatment decisions in patients with HR+/HER2- advanced breast cancer
- Discuss second-line treatment options for patients with HR+/HER2- advanced breast cancer who progress on a first-line CDK4/6 inhibitor
- Provide expert insights on relevant patient populations and treatment outcomes for these patients

## Agenda:

- Welcome and Introduction
- Survival Outcomes With First-Line CDK4/6i for Patients With HR+/HER2- Advanced Breast Cancer
- Second-Line Treatment Options for Patients With HR+/HER2- Advanced Breast Cancer
- Roundtable Discussion
- Key Takeaways and Live Q&A

This scientific information may include data information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.  
This program and/or materials were developed for use outside of the US, intended for non-US are HCPs, and are to be used in accordance with local laws and regulations.